{"id":"NCT00569192","sponsor":"Allergan","briefTitle":"A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Study Investigating the Safety and Efficacy Over 12 Weeks Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-09","completion":"2009-01","firstPosted":"2007-12-07","resultsPosted":"2013-10-23","lastUpdate":"2014-01-09"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"0.135mg MAP0010","otherNames":[]},{"type":"DRUG","name":"0.25mg MAP0010","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"0.25mg MAP0010","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"0.135mg MAP0010","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to examine the safety and efficacy of two doses of MAP0010 versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week treatment period.","primaryOutcome":{"measure":"Change From Baseline in Daytime Composite Symptom Score","timeFrame":"baseline, week 12","effectByArm":[{"arm":"Placebo","deltaMin":2.73,"sd":1.406},{"arm":"0.135 mg MAP0010","deltaMin":2.96,"sd":1.329},{"arm":"0.25 mg MAP0010","deltaMin":2.87,"sd":1.383}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":110},"commonTop":["Upper Respiratory Tract Infections","Asthma","Pyrexia","Nasopharyngitis"]}}